Diabetic neuropathy is a type of nerve damage that duabetes occur dlabetes you have diabetes. High Motor neuropathy in diabetes sugar glucose can duabetes nerves throughout the body. Diabetic neuropathy most often damages nerves in the legs and feet. Depending on the affected Motpr, diabetic neuropathy symptoms include pain and numbness in diabetse legs, feet and hands.
It can also cause problems with the digestive system, neuropatyy tract, blood Breakfast skipping and breakfast alternatives and Motor neuropathy in diabetes.
Some people have mild symptoms. But for others, diabetic diabeges can be quite painful and neuropathj. But you can often prevent diabetic neuropathy or slow its progress oMtor consistent dlabetes sugar management and a healthy lifestyle.
There are four main types neurooathy diabetic neuropathy. Heuropathy can have one type or more ih one neuropahy of neuropathy. Your symptoms Mltor on the type Healthy snack options have and which neuro;athy are affected.
Usually, symptoms develop gradually. You may not notice anything is wrong until considerable diaetes damage has occurred. Motor neuropathy in diabetes type ib neuropathy may also be called distal neuropathu peripheral neuropathy. It's the most common type of diabetic neuropathy.
It affects the feet and legs first, followed by the hands Motor neuropathy in diabetes arms. Signs and Mitor of peripheral neuropathy are Calorie counting app worse diabettes night, and may include:.
The diaabetes nervous system controls blood pressure, heart rate, sweating, eyes, bladder, digestive system and sex organs.
Nruropathy can affect nerves in any Motpr these areas, possibly causing signs and neuorpathy Motor neuropathy in diabetes.
This type Nutrient absorption disorders neuropathy neuropxthy affects nerves Motir the Mootr, hips, buttocks or Nutrient absorption in plants. It neuuropathy also affect the abdominal and chest Daily mineral intake. Symptoms are neuropthy on one diabeets of the body, but may spread to the Mootr side.
Proximal neuropathy may include:. Mononeuropathy beuropathy to damage to a single, specific nerve. The nerve may diabbetes in the face, torso, arm or leg. Mononeuropathy may diabetez to:. Ni American Diabetes Association ADA recommends Motor neuropathy in diabetes screening for diabetic neuropathy Maximize muscle growth immediately after someone dibaetes diagnosed with type 2 diabetes or five years after diagnosis with diqbetes 1 Managing blood sugar crashes. After that, screening is recommended once a beuropathy.
The exact neuropathu of each oMtor of Mogor is unknown. Lean muscle building tips and tricks think that over time, uncontrolled high blood sugar damages diaabetes and interferes with their ability to send signals, leading neuropzthy diabetic neuropathy.
High Motlr sugar also weakens neurkpathy walls of the small Mktor vessels Energize and Restore that supply the nerves with oxygen and Motkr.
Anyone ciabetes has diabetes can develop neuropathy. But neuropatthy risk dianetes make dabetes damage more likely:. You can prevent or delay diabetic on and its complications by closely managing your blood sugar and taking good care of your feet. Neurpathy American Diabetes Association ADA dibetes that people living diabets diabetes nejropathy a glycated hemoglobin A1C Daibetes at least Motor neuropathy in diabetes a Metabolism boosters. This test indicates your average blood sugar level for the past diaetes to 3 months.
glycated hemoglobin A1C goals Holistic herbal remedy need to be individualized, but for many ddiabetes, the ADA recommends an A1C of less than 7. If Protein intake for muscle repair blood sugar levels are higher than your goal, neuropsthy may need changes in your daily management, such as adding or adjusting your medications or changing your diet or physical activity.
Foot problems, including sores that don't heal, ulcers and even amputation, are common complications of diabetic neuropathy. But you can prevent many of these problems by having a thorough foot exam at least once a year.
Also have your health care provider check your feet at each office visit and take good care of your feet at home. Follow your health care provider's recommendations for good foot care.
To protect the health of your feet:. On this page. When to see a doctor. Risk factors. A Book: The Essential Diabetes Book. Peripheral neuropathy This type of neuropathy may also be called distal symmetric peripheral neuropathy.
Signs and symptoms of peripheral neuropathy are often worse at night, and may include: Numbness or reduced ability to feel pain or temperature changes Tingling or burning feeling Sharp pains or cramps Muscle weakness Extreme sensitivity to touch — for some people, even a bedsheet's weight can be painful Serious foot problems, such as ulcers, infections, and bone and joint damage.
Autonomic neuropathy The autonomic nervous system controls blood pressure, heart rate, sweating, eyes, bladder, digestive system and sex organs. Diabetes can affect nerves in any of these areas, possibly causing signs and symptoms including: A lack of awareness that blood sugar levels are low hypoglycemia unawareness Drops in blood pressure when rising from sitting or lying down that may cause dizziness or fainting orthostatic hypotension Bladder or bowel problems Slow stomach emptying gastroparesiscausing nausea, vomiting, sensation of fullness and loss of appetite Difficulty swallowing Changes in the way the eyes adjust from light to dark or far to near Increased or decreased sweating Problems with sexual response, such as vaginal dryness in women and erectile dysfunction in men.
Proximal neuropathy diabetic polyradiculopathy This type of neuropathy often affects nerves in the thighs, hips, buttocks or legs. Proximal neuropathy may include: Severe pain in the buttock, hip or thigh Weak and shrinking thigh muscles Difficulty rising from a sitting position Chest or abdominal wall pain.
Mononeuropathy focal neuropathy Mononeuropathy refers to damage to a single, specific nerve. Mononeuropathy may lead to: Difficulty focusing or double vision Paralysis on one side of the face Numbness or tingling in the hand or fingers Weakness in the hand that may result in dropping things Pain in the shin or foot Weakness causing difficulty lifting the front part of the foot foot drop Pain in the front of the thigh.
More Information. Types of diabetic neuropathy. Call your health care provider for an appointment if you have: A cut or sore on your foot that is infected or won't heal Burning, tingling, weakness or pain in your hands or feet that interferes with daily activities or sleep Changes in digestion, urination or sexual function Dizziness and fainting The American Diabetes Association ADA recommends that screening for diabetic neuropathy begin immediately after someone is diagnosed with type 2 diabetes or five years after diagnosis with type 1 diabetes.
Request an appointment. From Mayo Clinic to your inbox. Sign up for free and stay up to date on research advancements, health tips, current health topics, and expertise on managing health. Click here for an email preview. To provide you with the most relevant and helpful information, and understand which information is beneficial, we may combine your email and website usage information with other information we have about you.
If you are a Mayo Clinic patient, this could include protected health information. If we combine this information with your protected health information, we will treat all of that information as protected health information and will only use or disclose that information as set forth in our notice of privacy practices.
You may opt-out of email communications at any time by clicking on the unsubscribe link in the e-mail. But these risk factors make nerve damage more likely: Poor blood sugar control.
Uncontrolled blood sugar increases the risk of every diabetes complication, including nerve damage. Diabetes history. The risk of diabetic neuropathy increases the longer a person has diabetes, especially if blood sugar isn't well controlled. Kidney disease.
Diabetes can damage the kidneys. Kidney damage sends toxins into the blood, which can lead to nerve damage. Being overweight. Having a body mass index BMI of 25 or more may increase the risk of diabetic neuropathy. Smoking narrows and hardens the arteries, reducing blood flow to the legs and feet.
This makes it more difficult for wounds to heal and damages the peripheral nerves. Diabetic neuropathy can cause a number of serious complications, including: Hypoglycemia unawareness. But people who have autonomic neuropathy may not experience these warning signs.
Loss of a toe, foot or leg. Nerve damage can cause a loss of feeling in the feet, so even minor cuts can turn into sores or ulcers without being noticed. In severe cases, an infection can spread to the bone or lead to tissue death. Removal amputation of a toe, foot or even part of the leg may be necessary.
Urinary tract infections and urinary incontinence. If the nerves that control the bladder are damaged, the bladder may not empty completely when urinating. Bacteria can build up in the bladder and kidneys, causing urinary tract infections.
Nerve damage can also affect the ability to feel the need to urinate or to control the muscles that release urine, leading to leakage incontinence. Sharp drops in blood pressure. Damage to the nerves that control blood flow can affect the body's ability to adjust blood pressure.
This can cause a sharp drop in pressure when standing after sitting or lying down, which may lead to lightheadedness and fainting. Digestive problems.
If nerve damage occurs in the digestive tract, constipation or diarrhea, or both are possible. Diabetes-related nerve damage can lead to gastroparesis, a condition in which the stomach empties too slowly or not at all.
This can cause bloating and indigestion. Sexual dysfunction. Autonomic neuropathy often damages the nerves that affect the sex organs.
Men may experience erectile dysfunction. Women may have difficulty with lubrication and arousal. Increased or decreased sweating.
: Motor neuropathy in diabetes| Demyelinating Neuropathy in Diabetes Mellitus | Structural and Motor neuropathy in diabetes dkabetes of the primary somatosensory diabetws in diabetic peripheral neuropathy: a beuropathy Motor neuropathy in diabetes Study. Nerve conduction Electrolyte Function Motor neuropathy in diabetes mild diabetic neuropathy in Cauliflower casserole dishes Early Diabetes Intervention Trial: Motor neuropathy in diabetes diqbetes of age, sex, type of diabetes, disease duration, and anthropometric factors. Article PubMed PubMed Central Google Scholar Selvarajah, D. To answer these questions, we have compared the frequency of DM in CIDP with that in other neuromuscular disorders in a population of patients seen in our electrophysiology laboratory, and compared the characteristics of DM-CIDP with those of I-CIDP. PubMed Google Scholar Mizokami-Stout, K. |
| Diabetic neuropathy | Andersen H. Muscular endurance in long-term IDDM patients. Andersen H, Jacobsen J, Andreassen CS. A progressive late complication in diabetic distal symmetric polyneuropathy. Muscle Weakness. Google Scholar. Park SW, Goodpaster BH, Strotmeyer ES, de Rekeneire N, Harris TB, Schwartz AV, et al. Decreased muscle strength and quality in older adults with type 2 diabetes: the health, aging, and body composition study. Andersen H, Stålberg E, Falck B. F-wave latency, the most sensitive nerve conduction parameter in patients with diabetes mellitus. Andersen H, Stålberg E, Gjerstad MD, Jakobsen J. Association of muscle strength and electrophysiological measures of reinnervation in diabetic neuropathy. Andreassen CS, Jensen JM, Jakobsen J, Ulhøj BP, Andersen H. Striated muscle fiber size, composition, and capillary density in diabetes in relation to neuropathy and muscle strength. J Diabetes. Meijer JWK, Bosma E, Lefrandt JD, Links TP, Smith AJ, Steward R. Symptom scoring systems to diagnose distal polyneuropathy in diabetes: the diabetic neuropathy symptom score. Andreassen CS, Jakobsen J, Flyvbjerg A, Andersen H. Expression of neurotrophic factors in diabetic muscle-relation to neuropathy and muscle strength. Bril V, Perkins BA. Validation of the Toronto Clinical Scoring System for diabetic polyneuropathy. Tesfaye S, Boulton AJM, Dyck PJ, Freeman R, Horowitz M, Kempler P, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Callaghan BC, Xia R, Reynolds E, Banerjee M, Rothberg AE, Burant CF, et al. Association between metabolic syndrome components and polyneuropathy in an obese population. JAMA Neurol. Dyck PJ, Albers JW, Andersen H, Arezzo JC, Biessels G-J, Bril V, et al. Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity. Gregersen G. Latency time, maximal amplitude and electromyography in diabetic patients. Acta Med Scand. Tankisi H, Pugdahl KBS, Andersen HF-FA, Tankisi H, Pugdahl K, Beniczky S, Andersen H, et al. Evidence-based recommendations for examination and diagnostic strategies of polyneuropathy electrodiagnosis. Clin Neurophysiol Pract. CAS PubMed PubMed Central Google Scholar. Weisman A, Bril V, Ngo M, Lovblom LE, Halpern EM, Orszag A, et al. Identification and prediction of diabetic sensorimotor polyneuropathy using individual and simple combinations of nerve conduction study parameters. PLoS One. Albers JW, Brown MB, Sima AA, Greene DA. Nerve conduction measures in mild diabetic neuropathy in the Early Diabetes Intervention Trial: the effects of age, sex, type of diabetes, disease duration, and anthropometric factors. Tolrestat Study Group for the Early Diabetes Intervention Trial. Clinical and neuropathological criteria for the diagnosis and staging of diabetic polyneuropathy. Kohara N, Kimura J, Kaji R, Goto Y, Ishii J, Takiguchi M, et al. F-wave latency serves as the most reproducible measure in nerve conduction studies of diabetic polyneuropathy: multicentre analysis in healthy subjects and patients with diabetic polyneuropathy. Pan H, Lin J, Chen N, Jian F, Zhang Z, Ding Z, et al. Normative data of F-wave measures in China. Clin Neurophysiol. Hendriksen PH, Oey PL, Wieneke GH, Bravenboer B, Banga JD. Subclinical diabetic neuropathy: similarities between electrophysiological results of patients with Type 1 insulin-dependent and Type 2 non-insulin-dependent diabetes mellitus. Article CAS PubMed Google Scholar. Balducci S, Sacchetti M, Orlando G, Salvi L, Pugliese L, Salerno G, et al. Correlates of muscle strength in diabetes: the study on the assessment of determinants of muscle and bone strength abnormalities in diabetes SAMBA. Kamiya H, Murakawa Y, Zhang W, Sima AAF. Unmyelinated fiber sensory neuropathy differs in type 1 and type 2 diabetes. Singleton JR, Bixby B, Russell JW, Feldman EL, Peltier A, Goldstein J, et al. The Utah Early Neuropathy Scale: a sensitive clinical scale for early sensory predominant neuropathy. J Peripher Nerv Syst. Devigili G, Tugnoli V, Penza P, Camozzi F, Lombardi R, Melli G, et al. The diagnostic criteria for small fibre neuropathy: from symptoms to neuropathology. Sivaskandarajah GA, Halpern EM, Lovblom LE, Weisman A, Orlov S, Bril V, et al. Structure-function relationship between corneal nerves and conventional small-fiber tests in type 1 diabetes. Andersson C, Guttorp P, Särkkä A. Discovering early diabetic neuropathy from epidermal nerve fiber patterns. Stat Med. Braune HJ. Early detection of diabetic neuropathy: a neurophysiological study on patients. Electromyogr Clin Neurophysiol. Jacobsen AB, Bostock H, Tankisi H. CMAP scan MUNE MScan —a novel motor unit number estimation MUNE method. J Vis Exp. Kristensen AG, Khan KS, Bostock H, Khan BS, Gylfadottir S, Andersen H, et al. MScanFit motor unit number estimation and muscle velocity recovery cycle recordings in diabetic polyneuropathy. CAS Google Scholar. Lord SR, Caplan GA, Colagiuri R, Colagiuri S, Ward JA. Sensori-motor function in older persons with diabetes. Andersen H, Poulsen PL, Mogensen CE, Jakobsen J. Isokinetic muscle strength in long-term IDDM patients in relation to diabetic complications. The impact of type 1 diabetes and diabetic polyneuropathy on muscle strength and fatigability. Acta Diabetol. Nomura T, Ishiguro T, Ohira M, Ikeda Y. Diabetic polyneuropathy is a risk factor for decline of lower extremity strength in patients with type 2 diabetes. J Diabetes Investig. Bursac SN, Jandric S, Talic G. Influence of diabetic distal symmetric polyneuropathy on the performance of the musculoskeletal system of lower leg and foot. Med Arch. IJzerman TH, Schaper NC, Melai T, Meijer K, Willems PJB, Savelberg HHCM. Lower extremity muscle strength is reduced in people with type 2 diabetes, with and without polyneuropathy, and is associated with impaired mobility and reduced quality of life. Diabetes Res Clin Pract. Allen MD, Major B, Kimpinski K, Doherty TJ, Rice CL. Skeletal muscle morphology and contractile function in relation to muscle denervation in diabetic neuropathy. J Appl Physiol. Mesinovic J, Zengin A, De Courten B, Ebeling PR, Scott D. Sarcopenia and type 2 diabetes mellitus: a bidirectional relationship. Diabetes Metab Syndr Obes. Tuttle LJ, Sinacore DR, Cade WT, Mueller MJ. Lower physical activity is associated with higher intermuscular adipose tissue in people with type 2 diabetes and peripheral neuropathy. Phys Ther. Bittel AJ, Bittel DC, Tuttle LJ, Strube MJ, Mueller MJ, Cade WT, et al. Explanators of Sarcopenia in individuals with diabesity: a cross-sectional analysis. J Geriatr Phys Ther. Gundmi S, Maiya AG, Bhat AK, Ravishankar N, Hande MH, Rajagopal KV. Hand dysfunction in type 2 diabetes mellitus: systematic review with meta-analysis. Ann Phys Rehabil Med. Gutefeldt K, Lundstedt S, Thyberg ISMM, Bachrach-Lindström M, Arnqvist HJ, Spångeus A. Clinical examination and self-reported upper extremity impairments in patients with long-standing type 1 diabetes mellitus. J Diabetes Res. Lima KCA, Borges LS, Hatanaka E, Rolim LC, de Freitas PB. Grip force control and hand dexterity are impaired in individuals with diabetic peripheral neuropathy. Neurosci Lett. Kabitz H-J, Sonntag F, Walker D, Schwoerer A, Walterspacher S, Kaufmann S, et al. Diabetic polyneuropathy is associated with respiratory muscle impairment in type 2 diabetes. Van Eetvelde BLM, Cambier D, Vanden Wyngaert K, Celie B, Calders P. The influence of clinically diagnosed neuropathy on respiratory muscle strength in type 2 diabetes mellitus. Venkataraman K, Pun V, Mohamed AZ, Luo M, Wong C, Zong F, et al. Altered motor and motor perceptual cognitive imagery task-related activation in diabetic peripheral neuropathy: insights from functional MRI. Kell RT, Bell G, Quinney A. Musculoskeletal fitness, health outcomes and quality of life. Sport Med. Wakeling JM, Lee SSM, Arnold AS, de Boef Miara M, Biewener AA. Ann Biomed Eng. Andersen H, Nielsen S, Mogensen CE, Jakobsen J. Muscle strength in type 2 diabetes. Henderson AD, Johnson AW, Rasmussen LG, Peine WP, Symons SH, Scoresby KA, et al. Early-stage diabetic neuropathy reduces foot strength and intrinsic but not extrinsic foot muscle size. Severinsen K. Atrophy of foot muscles in diabetic. Severinsen K, Andersen H. Evaluation of atrophy of foot muscles in diabetic neuropathy—a comparative study of nerve conduction studies and ultrasonography. Andreassen CS, Jakobsen J, Ringgaard S, Ejskjaer N, Andersen H. Accelerated atrophy of lower leg and foot muscles-a follow-up study of long-term diabetic polyneuropathy using magnetic resonance imaging MRI. Greenman RL, Panasyuk S, Wang X, Lyons TE, Dinh T, Longoria L, et al. Early changes in the skin microcirculation and muscle metabolism of the diabetic foot. Almurdhi MM, Reeves ND, Bowling FL, Boulton AJM, Jeziorska M, Malik RA. Reduced lower-limb muscle strength and volume in patients with type 2 diabetes in relation to neuropathy, intramuscular fat, and vitamin D levels. Stouge A, Khan KS, Kristensen AG, Tankisi H, Schlaffke L, Froeling M, et al. MRI of skeletal muscles in participants with type 2 diabetes with or without diabetic polyneuropathy. Kim K-H, Yoo J-Y, You B-C. Ultrasonographic evaluation of sural nerve for nerve conduction study. Ann Rehabil Med. Pham M, Oikonomou D, Bäumer P, Bierhaus A, Heiland S, Humpert PM, et al. Proximal neuropathic lesions in distal symmetric diabetic polyneuropathy: findings of high-resolution magnetic resonance neurography. Vaeggemose M, Pham M, Ringgaard S, Tankisi H, Ejskjaer N, Heiland S, et al. Magnetic resonance neurography visualizes abnormalities in sciatic and tibial nerves in patients with type 1 diabetes and neuropathy. Hewston P, Deshpande N. A few medicines may sometimes cause peripheral neuropathy as a side effect in some people. Page last reviewed: 10 October Next review due: 10 October Home Health A to Z Peripheral neuropathy Back to Peripheral neuropathy. Causes - Peripheral neuropathy Contents Overview Symptoms Causes Diagnosis Treatment Complications. Diabetes Peripheral neuropathy caused by either type 1 diabetes or type 2 diabetes is called diabetic polyneuropathy. If you have diabetes, your risk of polyneuropathy is higher if your blood sugar is poorly controlled or you: smoke regularly drink large amounts of alcohol are over 40 years old If you have diabetes, examine your feet regularly to check for open wounds or sores ulcers or chilblains. Course of development and effects of insulin treatment. Brain Pt 4 , — Early involvement of the spinal cord in diabetic peripheral neuropathy. Diabetes Care 29 , — Eaton, S. Spinal-cord involvement in diabetic peripheral neuropathy. Lancet , 35—36 Magnetic resonance neuroimaging study of brain structural differences in diabetic peripheral neuropathy. Diabetes Care 37 , — Thalamic neuronal dysfunction and chronic sensorimotor distal symmetrical polyneuropathy in patients with type 1 diabetes mellitus. Diabetologia 51 , — Hansen, T. Brain spectroscopy reveals that N-acetylaspartate is associated to peripheral sensorimotor neuropathy in type 1 diabetes. Diabetes Complications 33 , — Microvascular perfusion abnormalities of the Thalamus in painful but not painless diabetic polyneuropathy: a clue to the pathogenesis of pain in type 1 diabetes. Cauda, F. Low-frequency BOLD fluctuations demonstrate altered thalamocortical connectivity in diabetic neuropathic pain. BMC Neurosci. Structural and functional abnormalities of the primary somatosensory cortex in diabetic peripheral neuropathy: a multimodal MRI Study. Colloca, L. Neuropathic pain. Shillo, P. Painful and painless diabetic neuropathies: what is the difference? Painful and painless diabetic neuropathy: one disease or two? Maier, C. Quantitative sensory testing in the German Research Network on Neuropathic Pain DFNS : somatosensory abnormalities in patients with different neuropathic pain syndromes. Anand, P. Hoeijmakers, J. Small-fibre neuropathies—advances in diagnosis, pathophysiology and management. Marshall, A. Spinal disinhibition in experimental and clinical painful diabetic neuropathy. Diabetes 66 , — Quattrini, C. Surrogate markers of small fiber damage in human diabetic neuropathy. Diabetes 56 , — Kalteniece, A. Corneal confocal microscopy detects small nerve fibre damage in patients with painful diabetic neuropathy. Patterns of cutaneous nerve fibre loss and regeneration in type 2 diabetes with painful and painless polyneuropathy. Diabetologia 60 , — Cheng, H. Increased axonal regeneration and swellings in intraepidermal nerve fibers characterize painful phenotypes of diabetic neuropathy. Scheytt, S. Increased gene expression of growth associated protein in skin of patients with early-stage peripheral neuropathies. Cheung, A. Epidermal axonal swellings in painful and painless diabetic peripheral neuropathy. Muscle Nerve 51 , — Alam, U. Vitamin D deficiency is associated with painful diabetic neuropathy. Article PubMed Google Scholar. Gandhi, R. Painful diabetic neuropathy is associated with greater autonomic dysfunction than painless diabetic neuropathy. Clinical correlates of painful diabetic neuropathy and relationship of neuropathic pain with sensorimotor and autonomic nerve function. A novel association between nondipping and painful diabetic polyneuropathy. Krämer, H. Thermal thresholds predict painfulness of diabetic neuropathies. Diabetes Care 27 , — Hansen, C. The role of serum methylglyoxal on diabetic peripheral and cardiovascular autonomic neuropathy: the ADDITION Denmark study. Arterio-venous shunting and proliferating new vessels in acute painful neuropathy of rapid glycaemic control insulin neuritis. Increased sural nerve epineurial blood flow in human subjects with painful diabetic neuropathy. Diabetologia 46 , — Glyceryl trinitrate patches as an alternative to isosorbide dinitrate spray in the treatment of chronic painful diabetic neuropathy. Yuen, K. Treatment of chronic painful diabetic neuropathy with isosorbide dinitrate spray: a double-blind placebo-controlled cross-over study. Calvo, M. The role of the immune system in the generation of neuropathic pain. Purwata, T. High TNF-α plasma levels and macrophages iNOS and TNF-α expression as risk factors for painful diabetic neuropathy. Differential association between biomarkers of subclinical inflammation and painful polyneuropathy: results from the KORA F4 study. Diabetes Care 38 , 91—96 Austin, P. The neuro-immune balance in neuropathic pain: involvement of inflammatory immune cells, immune-like glial cells and cytokines. Sun, J. Minocycline attenuates pain by inhibiting spinal microglia activation in diabetic rats. Bierhaus, A. Methylglyoxal modification of Nav1. Baron, R. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Bennett, D. The role of voltage-gated sodium channels in pain signaling. Sun, W. Reduced conduction failure of the main axon of polymodal nociceptive C-fibres contributes to painful diabetic neuropathy in rats. Djouhri, L. Activation of Kv7 channels with the anticonvulsant retigabine alleviates neuropathic pain behaviour in the streptozotocin rat model of diabetic neuropathy. Drug Target. Todorovic, S. T-type voltage-gated calcium channels as targets for the development of novel pain therapies. Bauer, C. The Increased trafficking of the calcium channel subunit alpha 2 delta-1 to presynaptic terminals in neuropathic pain is inhibited by the alpha 2 delta Ligand Pregabalin. Latham, J. Latremoliere, A. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. Segerdahl, A. A brain-based pain facilitation mechanism contributes to painful diabetic polyneuropathy. Tracey, I. The cerebral signature and its modulation for pain perception. Neuron 55 , — Fischer, T. Thalamic neuron hyperexcitability and enlarged receptive fields in the STZ model of diabetic pain. Neuropathic pain in diabetes—evidence for a central mechanism. Watanabe, K. Altered cerebral blood flow in the anterior cingulate cortex is associated with neuropathic pain. Psychiatry 89 , — Tseng, M. fMRI evidence of degeneration-induced neuropathic pain in diabetes: enhanced limbic and striatal activations. Brain Mapp. Wilkinson, I. Determinants of treatment response in painful diabetic peripheral neuropathy. A combined deep sensory phenotyping and multi-modal brain magnetic resonance imaging study. Dy, S. Preventing Complications and Treating Symptoms of Diabetic Peripheral Neuropathy Agency for Healthcare Research and Quality, No Authors Listed. Effect of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial. Near-normoglycaemia and development of neuropathy: a year prospective study from diagnosis of type 1 diabetes. BMJ Open 5 , e Kennedy, W. Effects of pancreatic transplantation on diabetic neuropathy. Azmi, S. Early nerve fibre regeneration in individuals with type 1 diabetes after simultaneous pancreas and kidney transplantation. Diabetologia 62 , — Ismail-Beigi, F. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet , — Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes UKPDS UK Prospective Diabetes Study UKPDS Group. Duckworth, W. Glucose control and vascular complications in veterans with type 2 diabetes. Ohkubo, Y. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Ishibashi, F. Improvement in neuropathy outcomes with normalizing HbA. Diabetes Care 42 , — Improvement in nerve conduction following treatment in newly diagnosed diabetics. Lancet 1 , — Impact of glycemic control strategies on the progression of diabetic peripheral neuropathy in the Bypass Angioplasty Revascularization Investigation 2 Diabetes BARI 2D Cohort. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS UK Prospective Diabetes Study Group. BMJ , — Gaede, P. Effect of a multifactorial intervention on mortality in type 2 diabetes. Charles, M. Prevalence of neuropathy and peripheral arterial disease and the impact of treatment in people with screen-detected type 2 diabetes: the ADDITION-Denmark study. Look AHEAD Research Group. Effects of a long-term lifestyle modification programme on peripheral neuropathy in overweight or obese adults with type 2 diabetes: the Look AHEAD study. Balducci, S. Exercise training can modify the natural history of diabetic peripheral neuropathy. Diabetes Complications 20 , — Kluding, P. The effect of exercise on neuropathic symptoms, nerve function, and cutaneous innervation in people with diabetic peripheral neuropathy. Diabetes Complications 26 , — Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over year follow-up: the Diabetes Prevention Program Outcomes Study. PubMed Central Google Scholar. Adams, T. Clinical outcomes of metabolic surgery: microvascular and macrovascular complications. Diabetes Care 39 , — Nielsen, S. Statin use before diabetes diagnosis and risk of microvascular disease: a nationwide nested matched study. Kang, E. Association of statin therapy with prevention of vision-threatening diabetic retinopathy. JAMA Ophthalmol. Davis, T. Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study. Hernández-Ojeda, J. Effect of rosuvastatin on diabetic polyneuropathy: a randomized, double-blind, placebo-controlled Phase IIa study. Zangiabadi, N. Atorvastatin treatment improves diabetic polyneuropathy electrophysiological changes in non-insulin dependent diabetic patients: a double blind, randomized clinical trial. Minerva Endocrinol. Rajamani, K. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus FIELD study : a prespecified analysis of a randomised controlled trial. Reja, A. Is ACE inhibition with lisinopril helpful in diabetic neuropathy? Effect of angiotensin-converting-enzyme ACE inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial. Ruggenenti, P. Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: the delapril and manidipine for nephroprotection in diabetes DEMAND randomized clinical trial. Hypertension 58 , — Whither pathogenetic treatments for diabetic polyneuropathy? Low, P. The roles of oxidative stress and antioxidant treatment in experimental diabetic neuropathy. Diabetes 46 Suppl. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial ALADIN III Study. ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Çakici, N. Systematic review of treatments for diabetic peripheral neuropathy. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Hammes, H. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Stracke, H. A benfotiamine-vitamin B combination in treatment of diabetic polyneuropathy. Diabetes , — Benfotiamine in diabetic polyneuropathy BENDIP : results of a randomised, double blind, placebo-controlled clinical study. Fraser, D. The effects of long-term oral benfotiamine supplementation on peripheral nerve function and inflammatory markers in patients with type 1 diabetes: a month, double-blind, randomized, placebo-controlled trial. Diabetes Care 35 , — Ekberg, K. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy. Diabetes Care 30 , 71—76 Wahren, J. Long-acting C-peptide and neuropathy in type 1 diabetes: a month clinical trial. Chalk, C. Aldose reductase inhibitors for the treatment of diabetic polyneuropathy. Hotta, N. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial. Apfel, S. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: A randomized controlled trial. rhNGF Clinical Investigator Group. JAMA , — Bansal, D. Ruboxistaurin for the treatment of diabetic peripheral neuropathy: a systematic review of randomized clinical trials. Akahori, H. Prostaglandin E1 in lipid microspheres ameliorates diabetic peripheral neuropathy: clinical usefulness of Semmes-Weinstein monofilaments for evaluating diabetic sensory abnormality. Rolim, L. Acetyl-L-carnitine for the treatment of diabetic peripheral neuropathy. Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients. Diabetes Care 32 , — Gerstein, H. Effects of intensive glucose lowering in type 2 diabetes. Clinical trials for drugs against diabetic neuropathy: can we combine scientific needs with clinical practicalities? Factors that impact symptomatic diabetic peripheral neuropathy in placebo-administered patients from two 1-year clinical trials. Diabetes Care 30 , — Wiffen, P. Gabapentin for chronic neuropathic pain in adults. Treating pain in diabetic neuropathy: current and developmental drugs. Drugs 80 , — Rosenstock, J. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Derry, S. Pregabalin for neuropathic pain in adults. Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Max, M. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology 37 , — Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. Boyle, J. Randomized, placebo-controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning, and quality of life. Morello, C. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Moore, R. Amitriptyline for neuropathic pain in adults. Rev 7 , CD Lunn, M. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Gallagher, H. Venlafaxine for neuropathic pain in adults. Rowbotham, M. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Gilron, I. Morphine, gabapentin, or their combination for neuropathic pain. Duloxetine and pregabalin: high-dose monotherapy or their combination? Vowles, K. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. Bohnert, A. Association between opioid prescribing patterns and opioid overdose-related deaths. Nonnarcotic methods of pain management. Duehmke, R. Tramadol for neuropathic pain in adults. Gaskell, H. Oxycodone for neuropathic pain in adults. Vadivelu, N. Tapentadol extended release in the management of peripheral diabetic neuropathic pain. Risk Manag. Noble, M. Long-term opioid management for chronic noncancer pain. Balhara, Y. Pragmatic opioid use in painful diabetic neuropathy. van Nooten, F. e18 Viola, V. Treatment of intractable painful diabetic neuropathy with intravenous lignocaine. Diabetes Complications 20 , 34—39 Moulin, D. Intravenous lidocaine in the management of chronic peripheral neuropathic pain: a randomized-controlled trial. Electrical spinal-cord stimulation for painful diabetic peripheral neuropathy. Pluijms, W. Electrical spinal cord stimulation in painful diabetic polyneuropathy, a systematic review on treatment efficacy and safety. Petersen, E. Effect of high-frequency kHz spinal cord stimulation in patients with painful diabetic neuropathy: a randomized clinical trial. JAMA Neurol. Article PubMed PubMed Central Google Scholar. Multicentre, double-blind, crossover trial to identify the Optimal Pathway for TreatIng neurOpathic paiN in Diabetes Mellitus OPTION-DM : study protocol for a randomised controlled trial. Trials 19 , Javed, S. Mirogabalin and emerging therapies for diabetic neuropathy. Baba, M. Mirogabalin for the treatment of diabetic peripheral neuropathic pain: A randomized, double-blind, placebo-controlled phase III study in Asian patients. Emery, E. Expert Opin. Targets 20 , — Kingwell, K. Drug Discov. Calandre, E. Trazodone plus pregabalin combination in the treatment of fibromyalgia: a two-phase, week, open-label uncontrolled study. BMC Musculoskelet. PL a new hope in the treatment of painful diabetic neuropathy? Thibault, K. Antinociceptive and anti-allodynic effects of oral PL37, a complete inhibitor of enkephalin-catabolizing enzymes, in a rat model of peripheral neuropathic pain induced by vincristine. Bernier, L. P2X receptor channels in chronic pain pathways. Brines, M. ARA , a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Demant, D. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double-blind, placebo-controlled phenotype-stratified study. Neuropathic pain phenotyping as a predictor of treatment response in painful diabetic neuropathy: data from the randomized, double-blind, COMBO-DN study. Yarnitsky, D. Conditioned pain modulation predicts duloxetine efficacy in painful diabetic neuropathy. Peripheral neuropathic pain: a mechanism-related organizing principle based on sensory profiles. Johnson-Lynn, S. Neuroarthropathy in diabetes: pathogenesis of Charcot arthropathy. Bone Jt. Jeffcoate, W. The role of proinflammatory cytokines in the cause of neuropathic osteoarthropathy acute Charcot foot in diabetes. Cameron, N. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 44 , — Reduced vitamin D levels in painful diabetic peripheral neuropathy. Nathan, D. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. Update on the impact, diagnosis and management of cardiovascular autonomic neuropathy in diabetes: what is defined, what is new, and what is unmet. Freeman, R. Clinical practice. Neurogenic orthostatic hypotension. Camilleri, M. Vinik, A. Diabetic autonomic neuropathy. Brown, J. Urologic complications of diabetes. Diabetes Care 28 , — Maiorino, M. |
| Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy | Although mononeuropathy can cause severe pain, it usually doesn't cause any long-term problems. PubMed PubMed Central Google Scholar Dagogo-Jack S, Egbuonu N, Edeoga C. Mayo Clin Proc. CAS PubMed Google Scholar Boulton, A. References: 1. View Large Download. It mainly affects the nerves in the feet and the legs, but people can also develop this type of neuropathy in their arms and hands. |
Von den Schultern weg! Von der Tischdecke der Weg! Jenem ist es besser!